Heterogeneity of tumor chemosensitivity in ovarian epithelial cancer revealed using the adenosine triphosphate-tumor chemosensitivity assay

Zhang,Jin; Li,Hongxia

doi:10.3892/ol.2015.3056

Heterogeneity of tumor chemosensitivity in ovarian epithelial cancer revealed using the adenosine triphosphate-tumor chemosensitivity assay

Authors:
- Jin Zhang
- Hongxia Li
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Beijing Shijitan Hospital, Capital Medical University, Haidian, Beijing 100038, P.R. China
Published online on: March 18, 2015 https://doi.org/10.3892/ol.2015.3056
Pages: 2374-2380

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer has a poor prognosis, primarily due to the heterogeneity in chemosensitivity among patients. In the present study, this heterogeneity was evaluated in ovarian epithelial cancer (OEC) using an in vitro adenosine triphosphate tumor chemosensitivity assay (ATP‑TCA). Specimens were collected from 80 patients who underwent cytoreductive surgery. Viable ovarian cancer cells obtained from malignant tissues were tested for sensitivity to paclitaxel (PTX), carboplatin (CBP), topotecan (TPT), gemcitabine (GEM), docetaxel (TXT), etoposide, bleomycin and 4‑hydroperoxycyclophosphamide using ATP‑TCA. The sensitivity, specificity, positive predictive value and negative predictive value for the clinical chemotherapy sensitivity of OEC were 88.6, 77.8, 83 and 84.8%, respectively. PTX demonstrated the highest sensitivity of all agents tested (82.5% in all specimens, 85.7% in recurrent specimens), followed by CBP (58.8 and 60.7%, respectively). The sensitivities to PTX and docetaxel (P<0.001) were correlated, in addition to those of CBP, TPT and GEM (P<0.001). Early‑stage (I/II) and high‑ to mildly‑differentiated OEC specimens revealed a lower chemosensitivity than advanced‑stage (III) or low‑differentiated specimens, respectively. The present study indicated that ATP‑TCA is an effective method for guiding the choice of chemotherapy drugs. Notable heterogeneity of chemosensitivity was observed in the OEC specimens.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
2	Armstrong DK and Brady MF: Intraperitoneal therapy for ovarian cancer: a treatment ready for prime time. J Clin Oncol. 24:4531–4533. 2006. View Article : Google Scholar : PubMed/NCBI
3	Gore M, du Bois A and Vergote I: Intraperitoneal chemotherapy in ovarian cancer remains experimental. J Clin Oncol. 24:4528–4530. 2006. View Article : Google Scholar : PubMed/NCBI
4	Bao B, Ahmad A, Azmi AS, Ali S and Sarkar FH: Overview of cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy. Curr Protoc Pharmacol. 14:Unit. 14–25. 2013.
5	Marusyk A and Polyak K: Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 1805:105–117. 2010.PubMed/NCBI
6	Glaysher S, Gabriel FG, Johnson P, et al: Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy. Br J Cancer. 103:656–662. 2010. View Article : Google Scholar : PubMed/NCBI
7	Meinhold-Heerlein I and Hauptmann S: The heterogeneity of ovarian cancer. Arch Gynecol Obstet. 289:237–239. 2014. View Article : Google Scholar : PubMed/NCBI
8	Glaysher S and Cree IA: Cell sensitivity assays: the ATP-based tumor chemosensitivity assay. Methods Mol Biol. 731:247–257. 2011. View Article : Google Scholar : PubMed/NCBI
9	Kurbacher CM and Cree IA: Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements. Methods Mol Med. 110:101–120. 2005.PubMed/NCBI
10	Qi CJ, Ning YL, Zhu YL, et al: In vitro chemosensitivity in breast cancer using ATP-tumor chemosensitivity assay. Arch Pharm Res. 32:1737–1742. 2009. View Article : Google Scholar : PubMed/NCBI
11	Sevin BU, Peng ZL, Perras JP, et al: Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing. Gynecol Oncol. 31:191–204. 1988. View Article : Google Scholar : PubMed/NCBI
12	Konecny G, Crohns C, Pegram M, et al: Correlation of drug response with the ATP tumor chemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol. 77:258–263. 2000. View Article : Google Scholar : PubMed/NCBI
13	Neubauer H, Stefanova M, Solomayer E, et al: Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer. Anticancer Res. 28:949–955. 2008.PubMed/NCBI
14	Zhao D, Zhang W, Li XG, et al: Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes. Zhonghua Fu Chan Ke Za Zhi. 46:193–198. 2011.[(In Chinese)]. PubMed/NCBI
15	Cree IA, Kurbacher CM, Lamont A, et al: A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs. 18:1093–1101. 2007. View Article : Google Scholar : PubMed/NCBI
16	Sharma S, Neale MH, Di Nicolantonio F, et al: Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer. 3:192003. View Article : Google Scholar : PubMed/NCBI
17	Cree IA, Kurbacher CM, Untch M, et al: Correlation of clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anticancer Drugs. 7:630–635. 1996. View Article : Google Scholar : PubMed/NCBI
18	Andreotti PE, Cree IA, Kurbacher CM, et al: Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res. 55:5276–5282. 1995.PubMed/NCBI
19	Ling ZQ, Qi CJ, Lu XX, et al: Heterogeneity of chemosensitivity in esophageal cancer using ATP-tumor chemosensitivity assay. Acta Pharmacol Sin. 33:401–406. 2012. View Article : Google Scholar : PubMed/NCBI
20	National Comprehensive Cancer Network: Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Version 1. 2013. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarianAccessed. February 13–2015.
21	Fung-Kee-Fung M, Oliver T, Elit L, et al: Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 14:195–208. 2007. View Article : Google Scholar : PubMed/NCBI
22	Parmar MK, Ledermann JA, Colombo N, et al: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 361:2099–2106. 2003. View Article : Google Scholar : PubMed/NCBI
23	Gynecologic Oncology Group; Markman M, Blessing J, Rubin SC, Connor J, Hanjani P and Waggoner S: Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 101:436–440. 2006. View Article : Google Scholar : PubMed/NCBI
24	Sharma R, Graham J, Mitchell H, Brooks A, Blagden S and Gabra H: Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer. Br J Cancer. 100:707–712. 2009. View Article : Google Scholar : PubMed/NCBI
25	Kyrgiou M, Salanti G, Pavlidis N, Paraskevaidis E and Ioannidis JP: Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst. 98:1655–1663. 2006. View Article : Google Scholar : PubMed/NCBI
26	Vergote I: Prognostic factors in stage I ovarian carcinoma. Verh K Acad Geneeskd Belg. 63:257–271. 2001.PubMed/NCBI
27	Gadducci A, Cosio S, Zola P, Sostegni B, Fuso L and Sartori E: Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: an Italian multicenter retrospective study. Int J Gynecol Cancer. 23:461–468. 2013. View Article : Google Scholar : PubMed/NCBI
28	Seidman JD, Yemelyanova AV, Khedmati F, et al: Prognostic factors for stage I ovarian carcinoma. Int J Gynecol Pathol. 29:1–7. 2010. View Article : Google Scholar : PubMed/NCBI
29	Chan JK, Tian C, Monk BJ, et al: Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer. 112:2202–2210. 2008. View Article : Google Scholar : PubMed/NCBI
30	Tropé C, Kaern J, Hogberg T, et al: Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann Oncol. 11:281–288. 2000. View Article : Google Scholar : PubMed/NCBI
31	Bertelsen K, Hølund B, Andersen JE, Nielsen K, Strøyer I and Ladehoff P: Prognostic factors and adjuvant treatment in early epithelial ovarian cancer. Int J Gynecol Cancer. 3:211–218. 1993. View Article : Google Scholar : PubMed/NCBI
32	Swart AC: on behalf of ICON collaborators: Long-term follow-up of women enrolled in a randomized trial of adjuvant chemotherapy for early stage ovarian cancer (ICON1). J Clin Oncol, ASCO Annual Meeting Proceedings Part I 25 (June 20 Supplement). 55092007.
33	Chan JK, Tian C, Teoh D, et al: Survival after recurrence is poor for women with early-stage high-risk ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 116:307–311. 2010. View Article : Google Scholar : PubMed/NCBI
34	Sinilnikova OM, Mazoyer S, Bonnardel C, et al: BRCA1 and BRCA2 mutations in breast and ovarian cancer syndrome: reflection on the Creighton University historical series of high risk families. Fam Cancer. 5:15–20. 2006. View Article : Google Scholar : PubMed/NCBI
35	Daly MB, Axilbund JE, Buys S, et al: Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw. 8:562–594. 2010.PubMed/NCBI